Drug General Information
Drug ID
D09VQZ
Former ID
DNC011108
Drug Name
4-((3',4'-Difluorobiphenyl-4-yl)methyl)pyridine
Drug Type
Small molecular drug
Indication Discovery agent Investigative [531085]
Structure
Download
2D MOL

3D MOL

Formula
C18H13F2N
Canonical SMILES
C1=CC(=CC=C1CC2=CC=NC=C2)C3=CC(=C(C=C3)F)F
InChI
1S/C18H13F2N/c19-17-6-5-16(12-18(17)20)15-3-1-13(2-4-15)11-14-7-9-21-10-8-14/h1-10,12H,11H2
InChIKey
KREPMUWCVWQPGH-UHFFFAOYSA-N
PubChem Compound ID
Target and Pathway
Target(s) Cytochrome P450 11B1, mitochondrial Target Info Inhibitor [531085]
17 alpha-hydroxylase-C17, 20-lyase Target Info Inhibitor [531085]
BioCyc Pathway Superpathway of steroid hormone biosynthesis
Glucocorticoid biosynthesis
Mineralocorticoid biosynthesisPWY-7305:Superpathway of steroid hormone biosynthesis
Androgen biosynthesis
KEGG Pathway Steroid hormone biosynthesis
Metabolic pathwayshsa00140:Steroid hormone biosynthesis
Metabolic pathways
Ovarian steroidogenesis
Prolactin signaling pathway
PathWhiz Pathway SteroidogenesisPW000045:Androgen and Estrogen Metabolism
Steroidogenesis
Reactome Glucocorticoid biosynthesis
Endogenous sterolsR-HSA-193048:Androgen biosynthesis
Endogenous sterols
WikiPathways Metapathway biotransformation
Oxidation by Cytochrome P450
Metabolism of steroid hormones and vitamin D
Corticotropin-releasing hormoneWP702:Metapathway biotransformation
Steroid Biosynthesis
Glucocorticoid & Mineralcorticoid Metabolism
Prostate Cancer
Phase 1 - Functionalization of compounds
References
Ref 531085J Med Chem. 2010 Aug 12;53(15):5749-58.Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Ref 531085J Med Chem. 2010 Aug 12;53(15):5749-58.Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.